Riociguat for the treatment of pulmonary arterial hypertension associated with connective tissue disease: results from PATENT-1 and PATENT-2

BACKGROUND: The 12-week, phase III Pulmonary Arterial hyperTENsion sGC-stimulator Trial (PATENT)-1 study investigated riociguat in patients with pulmonary arterial hypertension (PAH). Here, we present a prospectively planned analysis of the safety and efficacy of riociguat in the subgroup of patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Humbert, Marc, Coghlan, J Gerry, Ghofrani, Hossein-Ardeschir, Grimminger, Friedrich, He, Jian-Guo, Riemekasten, Gabriela, Vizza, Carmine Dario, Boeckenhoff, Annette, Meier, Christian, de Oliveira Pena, Janethe, Denton, Christopher P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5284330/
https://www.ncbi.nlm.nih.gov/pubmed/27457511
http://dx.doi.org/10.1136/annrheumdis-2015-209087

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5284330/
https://www.ncbi.nlm.nih.gov/pubmed/27457511
http://dx.doi.org/10.1136/annrheumdis-2015-209087

Ejemplares similares